Here, we found that DOCK1 was significantly upregulated in HCC (Figs. 5E–G and S5B) and that targeting DOCK1 with selective inhibitor resulted in strong synergistic anti-tumor effects when administered with metformin (Fig. 4A, 4C, 4D and 4F). The gene discussed is DOCK1; the disease is neoplasm.